Editas Begin Period Cash Flow from 2010 to 2024
| EDIT Stock | USD 2.38 0.06 2.46% |
Begin Period Cash Flow | First Reported 2014-12-31 | Previous Quarter 69.2 M | Current Value 64.4 M | Quarterly Volatility 101.1 M |
Check Editas Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Editas Medicine's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.2 M, Interest Expense of 3 M or Selling General Administrative of 57.9 M, as well as many indicators such as Price To Sales Ratio of 9.36, Dividend Yield of 0.0 or PTB Ratio of 2.31. Editas financial statements analysis is a perfect complement when working with Editas Medicine Valuation or Volatility modules.
Editas | Begin Period Cash Flow |
Latest Editas Medicine's Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Editas Medicine over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Editas Medicine's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Editas Medicine's overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Editas Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 101,439,751 | |
| Geometric Mean | 31,477,858 | |
| Coefficient Of Variation | 86.01 | |
| Mean Deviation | 78,394,068 | |
| Median | 143,180,000 | |
| Standard Deviation | 87,250,650 | |
| Sample Variance | 7612.7T | |
| Range | 237.8M | |
| R-Value | 0.82 | |
| Mean Square Error | 2735.3T | |
| R-Squared | 0.67 | |
| Significance | 0.0002 | |
| Slope | 15,925,957 | |
| Total Sum of Squares | 106577.5T |
Editas Begin Period Cash Flow History
About Editas Medicine Financial Statements
Editas Medicine shareholders use historical fundamental indicators, such as Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Editas Medicine investors may analyze each financial statement separately, they are all interrelated. The changes in Editas Medicine's assets and liabilities, for example, are also reflected in the revenues and expenses on on Editas Medicine's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 145.4 M | 150 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.